• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Antiviral therapy improves survival in patients with HBV infection and intrahepatic cholangiocarcinoma undergoing liver resection: Novel concerns.

作者信息

Sha Meng, Jeong Seogsong, Xia Qiang

机构信息

Department of Liver Surgery, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, China.

Department of Liver Surgery, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, China.

出版信息

J Hepatol. 2018 Jun;68(6):1315-1316. doi: 10.1016/j.jhep.2018.01.039. Epub 2018 Feb 20.

DOI:10.1016/j.jhep.2018.01.039
PMID:29475065
Abstract
摘要

相似文献

1
Antiviral therapy improves survival in patients with HBV infection and intrahepatic cholangiocarcinoma undergoing liver resection: Novel concerns.抗病毒治疗可提高接受肝切除的乙肝病毒感染合并肝内胆管癌患者的生存率：新的关注点。
J Hepatol. 2018 Jun;68(6):1315-1316. doi: 10.1016/j.jhep.2018.01.039. Epub 2018 Feb 20.
2
Reply to: "Antiviral therapy improves survival in patients with HBV infection and intrahepatic cholangiocarcinoma undergoing liver resection: Novel concerns".回复：“抗病毒治疗可提高接受肝切除的HBV感染合并肝内胆管癌患者的生存率：新的关注点”
J Hepatol. 2018 Jun;68(6):1316-1318. doi: 10.1016/j.jhep.2018.02.010. Epub 2018 Feb 17.
3
Antiviral therapy improves survival in patients with HBV infection and intrahepatic cholangiocarcinoma undergoing liver resection.抗病毒治疗可改善 HBV 感染和肝内胆管细胞癌患者行肝切除术后的生存。
J Hepatol. 2018 Apr;68(4):655-662. doi: 10.1016/j.jhep.2017.11.015. Epub 2017 Nov 16.
4
Comparative analysis of resection and liver transplantation for intrahepatic and hilar cholangiocarcinoma: a 24-year experience in a single center.肝内胆管癌和肝门部胆管癌切除术与肝移植的比较分析：单中心24年经验
Arch Surg. 2011 Jun;146(6):683-9. doi: 10.1001/archsurg.2011.116.
5
Left hepatectomy or left trisectionectomy with resection of the caudate lobe and extrahepatic bile duct for hilar cholangiocarcinoma (with video).左半肝切除术或左三叶切除术联合尾叶切除和肝外胆管切除治疗肝门部胆管癌（附视频）。
J Hepatobiliary Pancreat Sci. 2012 May;19(3):195-202. doi: 10.1007/s00534-011-0474-6.
6
Surgical management of recurrent intrahepatic cholangiocellular carcinoma after liver resection.肝切除术后复发性肝内胆管细胞癌的外科治疗
Surgery. 2005 Jun;137(6):669-70. doi: 10.1016/j.surg.2005.03.007.
7
Letter to the Editor: Short- and Long-Term Outcomes of Liver Resection for Intrahepatic Cholangiocarcinoma Associated with the Metabolic Syndrome.致编辑的信：肝切除治疗与代谢综合征相关的肝内胆管癌的短期和长期预后
World J Surg. 2020 Mar;44(3):1002-1003. doi: 10.1007/s00268-019-05318-y.
8
[Importance of repeated liver resection in recurrent intrahepatic cholangiocarcinoma].[重复肝切除术在复发性肝内胆管癌中的重要性]
Chirurg. 2017 Sep;88(9):804. doi: 10.1007/s00104-017-0484-2.
9
Prognosis after resection for hepatitis B virus-associated intrahepatic cholangiocarcinoma.乙型肝炎病毒相关性肝内胆管癌切除术后的预后
World J Gastroenterol. 2015 Jan 21;21(3):935-43. doi: 10.3748/wjg.v21.i3.935.
10
Prognostic impact of hepatitis B virus infection in patients with intrahepatic cholangiocarcinoma.乙型肝炎病毒感染对肝内胆管癌患者的预后影响
ANZ J Surg. 2018 Mar;88(3):212-217. doi: 10.1111/ans.13753. Epub 2016 Sep 6.

引用本文的文献

1
Analysis of viral integration reveals new insights of oncogenic mechanism in HBV-infected intrahepatic cholangiocarcinoma and combined hepatocellular-cholangiocarcinoma.病毒整合分析揭示了乙型肝炎病毒感染的肝内胆管癌和肝细胞癌-胆管细胞癌合并癌中致癌机制的新见解。
Hepatol Int. 2022 Dec;16(6):1339-1352. doi: 10.1007/s12072-022-10419-3. Epub 2022 Sep 20.
2
Preoperative serum hepatitis B virus DNA was a risk factor for hepatocellular carcinoma recurrence after liver transplantation.术前血清乙型肝炎病毒 DNA 是肝移植后肝细胞癌复发的危险因素。
Ann Med. 2022 Dec;54(1):2213-2221. doi: 10.1080/07853890.2022.2107233.
3
Real-world outcomes of patients with advanced intrahepatic cholangiocarcinoma treated with programmed cell death protein-1-targeted immunotherapy.
接受程序性死亡蛋白-1 靶向免疫治疗的晚期肝内胆管癌患者的真实世界结局。
Ann Med. 2022 Dec;54(1):803-811. doi: 10.1080/07853890.2022.2048416.
4
Study on the Application of Doxorubicin-Loaded Magnetic Nanodrugs in Targeted Therapy of Liver Cancer.阿霉素负载磁性纳米药物在肝癌靶向治疗中的应用研究
Appl Bionics Biomech. 2022 Feb 22;2022:2756459. doi: 10.1155/2022/2756459. eCollection 2022.
5
Long Non-Coding RNA PCAT6 Induces M2 Polarization of Macrophages in Cholangiocarcinoma Modulating miR-326 and RhoA-ROCK Signaling Pathway.长链非编码RNA PCAT6通过调控miR-326和RhoA-ROCK信号通路诱导胆管癌中巨噬细胞的M2极化
Front Oncol. 2021 Jan 21;10:605877. doi: 10.3389/fonc.2020.605877. eCollection 2020.
6
lncRNA FLVCR1-AS1 regulates cell proliferation, migration and invasion by sponging miR-485-5p in human cholangiocarcinoma.长链非编码RNA FLVCR1-AS1通过海绵吸附miR-485-5p调控人胆管癌细胞的增殖、迁移和侵袭。
Oncol Lett. 2019 Sep;18(3):2240-2247. doi: 10.3892/ol.2019.10577. Epub 2019 Jul 5.
7
Negative impact of hepatitis B surface seroclearance on prognosis of hepatitis B-related primary liver cancer.乙肝表面血清学清除对乙肝相关原发性肝癌预后的负面影响。
World J Clin Cases. 2018 Aug 16;6(8):192-199. doi: 10.12998/wjcc.v6.i8.192.